Latest Breaking News On - கூட்டாளர் சிகிச்சை இன்க் - Page 2 : comparemela.com

Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications FX-06 is a synthetic peptide with a broad spectrum of potential applications associated with endothelial barrier integrity, blood vessel permeability and inflammation Potential applications include COVID-19, pandemic, chemical, biological, radiological and nuclear threats News provided by Share this article Share this article LEXINGTON, Mass., March 3, 2021 /PRNewswire/  Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces a licensing and collaboration agreement with Munich-based SIRS Theraputics and Vienna-based F4 Pharma to support the development of FX-06, a synthetic peptide that has a broad spectrum of potential indications.  The partnership will focus on exploring potential collaborations with the U.S. Government to develop FX-06 as a medical countermeasure against high priority threats for which there are s

New zealand generalNew zealandJohn mcmanusAnne burgerDebasish roychowdhuryPartner therapeutics incBiomedical advanced researchDepartment of defense joint program executive officeStrategic nationalChemical biological radiological nuclearDevelopment authorityPartner therapeuticsPartners therapeuticsChief technology officerChief business officerDefense joint program executive office